Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Malaria Vaccines R78C and RH5.1
NCT05385471Phase 1Active, not recruiting
- Sponsor
- University of Oxford
- Start
- Jan 2023
- Primary completion
- Mar 2026
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of R78C and RH5.1 in Malaria (4 arms), sponsored by University of Oxford. Primary endpoints: Solicited Local Reactogenicity Signs and Symptoms, Solicited Systemic Reactogenicity Signs and Symptoms and 3 more. Started Jan 2023; status: active, not recruiting.
02
Drugs
R78CRH5.1
03
Conditions
Malaria
Beyond the preview
Go deeper on NCT05385471.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05385471.